白雲山(00874.HK)分公司獲得藥品補充申請批件
格隆匯11月6日丨白雲山(00874.HK)公吿,近日,廣州白雲山醫藥集團股份有限公司(以下簡稱“本公司”)分公司廣州白雲山醫藥集團股份有限公司白雲山製藥總廠(以下簡稱“白雲山製藥總廠”)收到國家藥品監督管理局(以下簡稱“國家藥監局”)簽發的《藥品補充申請批准通知書》。
白雲山製藥總廠本次獲得枸櫞酸西地那非片《藥品補充申請批准通知書》,豐富了其藥品的種類,有利於提升本公司在醫藥市場的競爭力。白雲山製藥總廠將按照相關要求和市場需求開展生產。白雲山製藥總廠本次獲得桑菊感冒顆粒《藥品補充申請批准通知書》,完善了該藥品的安全性信息,有利於提升該產品的市場競爭力。本次獲得上述藥品補充申請批准通知書,對本公司當期業績無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.